Market Place
Sourcing Support
Biophytis Expands Asian Presence With Two Local Agent Contracts
23 Jul 2024 //
PHARMABIZ
Biophytis Gets FDA IND Approval For Phase 2 OBA Obesity Study
10 Jul 2024 //
ACCESSWIRE
Biophytis Presented its Ph 2-3 COVA Study Results in Severe Forms of Covid-19
01 Jul 2024 //
ACCESSWIRE
Biophytis Extends Contract With Atlas For Business Financing
19 Jun 2024 //
ACCESSWIRE
Biophytis Announces Successful Industrial Transfer Of BIO101 Production To Seqens
12 Jun 2024 //
PRESS RELEASE
Combined General Meeting of June 24, 2024
07 Jun 2024 //
ACCESSWIRE
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
14 May 2024 //
ACCESSWIRE
Biophytis Announces Transfer of ADSs to OTC Market
24 Apr 2024 //
ACCESSWIRE
Biophytis Announces ADR Ratio Change
19 Apr 2024 //
ACCESSWIRE
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA
17 Apr 2024 //
ACCESSWIRE
Biophytis launches OBA phase 2 clinical study in obesity with BIO101
08 Apr 2024 //
ACCESSWIRE
Biophytis Announces Its 2023 Financial Results
08 Apr 2024 //
ACCESSWIRE
Results of the Combined General Meeting on April 2, 2024
04 Apr 2024 //
ACCESSWIRE
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
22 Mar 2024 //
ACCESSWIRE
Biophytis And Skyepharma Sign A Partnership Agreement For Bio101
25 Sep 2023 //
PRESS RELEASE
Biophytis Provides An Update On Its Early Access Programs For Sarconeos
19 Sep 2023 //
PRESS RELEASE
Biophytis Strengthens Its Management Team With The Appointment Of Its Cbo
14 Sep 2023 //
PRESS RELEASE
25th annual H.C. Wainwright Global Investment Conference
12 Sep 2023 //
PRESS RELEASE
Biophytis Obtains Fda Authorization To Initiate Sara-31 Phase 3 In Sarcopenia
11 Sep 2023 //
PRESS RELEASE
Biophytis has Requested Pre-Submission Meeting with FDA for EUA of Sarconeos
20 Jul 2023 //
ACCESSWIRE
Biophytis Announces $3.8 Million Registered Direct Offering
19 Jul 2023 //
ACCESSWIRE
Biophytis and Seqens Sign a Partnership to Produce Sarconeos Active Compound
18 Jul 2023 //
PRESS RELEASE
Biophytis seeks US FDA approval to initiate SARA-31 phase 3 study in sarcopenia
10 Jul 2023 //
PHARMABIZ
Biophytis Reports Clinical Results for Sarconeos BIO101 in Sarcopenia Treatment
19 Jun 2023 //
ACCESSWIRE
Biophytis: Results of the Annual General Meeting June 16, 2023 All Resolutions
16 Jun 2023 //
ACCESSWIRE
Biophytis to Participate at the BIO International Convention in Boston
05 Jun 2023 //
ACCESSWIRE
Biophytis has Filed with the HAS an Application for EAA for Sarconeos
26 May 2023 //
ACCESSWIRE
Biophytis Presented Positive Results of Phase 2-3 COVA Study
25 May 2023 //
ACCESSWIRE
Biophytis has Filed with the EMA for Authorization to Initiate SARA-31 Ph3 Study
15 May 2023 //
ACCESSWIRE
Successful Capital Increase for Biophytis with €2.3 million Raised
11 May 2023 //
ACCESSWIRE
Biophytis has Requested a Pre-Submission with EMA for the Marketing of Sarconeos
09 May 2023 //
ACCESSWIRE
Biophytis strengthens its management team
02 May 2023 //
PHARMIWEB
Biophytis announces receipt of Nasdaq Notice
28 Apr 2023 //
PHARMIWEB
Biophytis Regains Compliance with NASDAQ Minimum Bid Price Requirement
19 Apr 2023 //
ACCESSWIRE
Biophytis Announces 2022 Financial Results and 2023 Perspectives
18 Apr 2023 //
ACCESSWIRE
Biophytis: Results of the Combined General Meeting on April 17, 2023
18 Apr 2023 //
ACCESSWIRE
Biophytis Presented Sarconeos (BIO101) As A Possible Treatment Candidate
27 Mar 2023 //
ACCESSWIRE
Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS
09 Mar 2023 //
ACCESSWIRE
Biophytis Announces Signature of a Master Service Agreement With Intsel Chimos
02 Mar 2023 //
ACCESSWIRE
Biophytis Initiates the Regulatory Process for Access Authorization in France
27 Feb 2023 //
ACCESSWIRE
Biophytis To Host a Combined General Shareholder’s Meeting on March 30, 2023
23 Feb 2023 //
ACCESSWIRE
Biophytis Announces Positive Results of the Phase 2-3 COVA Study with Sarconeos
02 Feb 2023 //
ACCESSWIRE
Biophytis Publishes its Financial Results for the First Half of 2022
31 Jan 2023 //
ACCESSWIRE
Biophytis receives a deficiency notice from Nasdaq Stock Market
14 Jan 2023 //
PHARMABIZ
Biophytis Announces Participation in Investor Conferences In the US & France
05 Jan 2023 //
ACCESSWIRE
Biophytis Organises a Webcast with Key Opinion Leaders On Ph2-3 Cova Study
01 Dec 2022 //
ACCESSWIRE
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Study
03 Nov 2022 //
BIOSPACE
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment
15 Sep 2022 //
ACCESSWIRE
The Paris Court of Appeal Rules in Favour of Biophytis in Case Against Negma
12 Sep 2022 //
ACCESSWIRE
Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA
06 Sep 2022 //
ACCESSWIRE
Biophytis Presents the Development of Sarconeos (BIO101) in PIII for Sarcopenia
27 Jun 2022 //
ACCESSWIRE
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in SMA
15 Jun 2022 //
ACCESSWIRE
Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia
19 Apr 2022 //
ACCESSWIRE
Biophytis Announces 2021 Operational and Financial Results
07 Apr 2022 //
ACCESSWIRE
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development
07 Apr 2022 //
ACCESSWIRE
Biophytis Appoints Philippe Rousseau as Chief Financial Officer
05 Apr 2022 //
ACCESSWIRE
Biophytis Received Approval from ANVISA to Give Access to Sarconeos (BIO101)
03 Feb 2022 //
ACCESSWIRE
Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2
15 Nov 2021 //
BIOSPACE
Biophytis Announces Promising Full From the SARA-INT Ph2b Trial Sarconeos BIO101
04 Oct 2021 //
GLOBENEWSWIRE
Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020
04 Oct 2021 //
GLOBENEWSWIRE
